Publications

Detailed Information

CD4(+) T(H)1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8(+) T Cells

DC Field Value Language
dc.contributor.authorPark, Jae Yeo-
dc.contributor.authorJin, Dong-Hoon-
dc.contributor.authorLee, Chang-Min-
dc.contributor.authorJang, Min Ja-
dc.contributor.authorShin, Hyo Seon-
dc.contributor.authorKim, Kyung Yong-
dc.contributor.authorLee, Won Bok-
dc.contributor.authorLee, Wang Jae-
dc.contributor.authorKim, Daejin-
dc.contributor.authorPark, Yeong-Min-
dc.contributor.authorShin, Yong Kyoo-
dc.contributor.authorKim, Sung Su-
dc.contributor.authorChung, Yoon Hee-
dc.contributor.authorLee, Sun Young-
dc.date.accessioned2012-07-10T02:20:15Z-
dc.date.available2012-07-10T02:20:15Z-
dc.date.issued2010-06-
dc.identifier.citationJOURNAL OF IMMUNOTHERAPY; Vol.33(5); 510-522ko_KR
dc.identifier.issn1524-9557-
dc.identifier.urihttps://hdl.handle.net/10371/78689-
dc.description.abstractThe requirement for CD4(+) T cells in priming and maintaining cytotoxic T-lymphocyte responses presents a long-standing paradox in cellular immunology. In this study, we used sequential coadministration of a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii-peptide region is replaced with CD4(+) T-helper epitope, PADRE [Pan human leukocyte antigen-DR reactive epitope (Ii-PADRE)] or BclxL with a DNA vaccine encoding Sig/E7/LAMP-1 to verify the role of CD4(+) T cells for the generation of effectors and memory E7-specific CD8(+) T-cell immune responses. Sequential vaccination, with Ii-PADRE + Sig/E7/LAMP-1 priming followed by BclxL + Sig/E7/LAMP-1 boosting led to generation of E7-specific CD8(+) T cells, and was nearly equivalent in effect to coadministration with Ii-PADRE+Sig/E7/LAMP-1 or Bcl-xL + Sig/E7/LAMP-1 at both prime and boost. The mice vaccinated with the Ii-PADRE+Sig/E7/LAMP-1 prime-Bcl-xL + Sig/E7/LAMP-1 boost regimen exhibited better long-term E7-specific immune responses and tumor prevention effects in vivo than the mice vaccinated with the reverse sequential coadministration. After CD4+ T-cell depletion, mice primed with Ii-PADRE+Sig/E7/LAMP-1 generated low numbers of E7-specific CD8(+) T cells and suppressed long-term memory CD8(+) T-cell response regardless of the sequence or combination of DNA vaccines administered. Mice primed with Bcl-xL + Sig/E7/LAMP-1 only suppressed long-term memory CD8(+) T-cell response after depletion of CD4(+) T cells before priming. Our findings suggest that activated CD4(+) T cells at prime phase are important to generate the antigen-specific CD8(+) T-cell immune responses and CD4(+) T cells, which are naive or activated, play a role to maintain the long-term memory responses.ko_KR
dc.description.sponsorshipSupported by the Korea Research Foundation Grant funded by the
Korean Government (KRF-2008-314-E00195).
ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectDNA vaccineko_KR
dc.subjectBcl-xLko_KR
dc.subjectprime-boostko_KR
dc.subjectIi-PADREko_KR
dc.subjectE7ko_KR
dc.titleCD4(+) T(H)1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8(+) T Cellsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박재여-
dc.contributor.AlternativeAuthor진동훈-
dc.contributor.AlternativeAuthor이창민-
dc.contributor.AlternativeAuthor장민자-
dc.contributor.AlternativeAuthor이선영-
dc.contributor.AlternativeAuthor신효선-
dc.contributor.AlternativeAuthor정윤희-
dc.contributor.AlternativeAuthor김경용-
dc.contributor.AlternativeAuthor김성수-
dc.contributor.AlternativeAuthor이원복-
dc.contributor.AlternativeAuthor신용규-
dc.contributor.AlternativeAuthor이왕재-
dc.contributor.AlternativeAuthor박영민-
dc.contributor.AlternativeAuthor김대진-
dc.identifier.doi10.1097/CJI.0b013e3181d75cef-
dc.citation.journaltitleJOURNAL OF IMMUNOTHERAPY-
dc.description.citedreferenceKim D, 2008, GENE THER, V15, P677, DOI 10.1038/sj.gt.3303102-
dc.description.citedreferenceKim DJ, 2007, HUM GENE THER, V18, P1129, DOI 10.1089/hum.2007.090-
dc.description.citedreferenceHung CF, 2007, MOL THER, V15, P1211, DOI 10.1038/sj.mt.6300121-
dc.description.citedreferenceTsen SWD, 2007, EXPERT REV VACCINES, V6, P227, DOI 10.1586/14760584.6.2.227-
dc.description.citedreferenceMueller SN, 2006, J IMMUNOL, V176, P7379-
dc.description.citedreferenceCastellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825-
dc.description.citedreferenceHUNG CF, 2006, METH MOLEC MED, V127, P199-
dc.description.citedreferencePeng SW, 2004, J VIROL, V78, P8468, DOI 10.1128/JVI.78.16.8468-8476.2004-
dc.description.citedreferenceFujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317-
dc.description.citedreferenceBehrens GMN, 2004, J IMMUNOL, V172, P5420-
dc.description.citedreferenceLin CT, 2003, MOL THER, V8, P559, DOI 10.1016/S1525-0016(03)00238-7-
dc.description.citedreferenceKim TW, 2003, J IMMUNOL, V171, P2970-
dc.description.citedreferenceKim TW, 2003, J CLIN INVEST, V112, P109, DOI 10.1172/JCI200317293-
dc.description.citedreferenceJanssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441-
dc.description.citedreferenceOuaaz F, 2002, IMMUNITY, V16, P257-
dc.description.citedreferenceMedema JP, 2001, J EXP MED, V194, P657-
dc.description.citedreferenceden Boer AT, 2001, J IMMUNOL, V167, P2522-
dc.description.citedreferenceAllen TM, 2000, J IMMUNOL, V164, P4968-
dc.description.citedreferenceChen CH, 2000, CANCER RES, V60, P1035-
dc.description.citedreferenceJosien R, 2000, J EXP MED, V191, P495-
dc.description.citedreferenceGurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927-
dc.description.citedreferenceJi HX, 1999, HUM GENE THER, V10, P2727-
dc.description.citedreferenceKent SJ, 1998, J VIROL, V72, P10180-
dc.description.citedreferenceKlenerman P, 1998, NATURE, V394, P482-
dc.description.citedreferenceMcMichael AJ, 1998, NATURE, V394, P421-
dc.description.citedreferenceIrvine KR, 1997, J NATL CANCER I, V89, P1595-
dc.description.citedreferenceJaiswal AI, 1997, J IMMUNOL, V159, P2282-
dc.description.citedreferenceDONNELLY JJ, 1997, LIFE SCI, V60, P163-
dc.description.citedreferenceCella M, 1996, J EXP MED, V184, P747-
dc.description.citedreferenceLin KY, 1996, CANCER RES, V56, P21-
dc.description.citedreferenceKEENE JA, 1982, J EXP MED, V155, P768-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share